BCL‐2, B‐cell lymphoma 2; EOC, epithelial ovarian cancer; FBP1, fructose‐bisphosphatase 1; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; NAMPT, nicotinamide phosphoribosyltransferase; PARP, poly(ADP‐ribose) polymerase; TNBC, triple‐negative breast cancer; TOP1, topoisomerase 1; uPAR, urokinase‐type plasminogen activator receptor. This evidence concerns the gene BCL2 and ovarian carcinoma.